Seeking Alpha

Dendreon (DNDN) -8.6% premarket after data from Johnson & Johnson (JNJ) and Medivation...

Dendreon (DNDN) -8.6% premarket after data from Johnson & Johnson (JNJ) and Medivation (MDVN) at the ASCO conference increases competitive pressure for DNDN's Provenge cancer drug. Patients taking JNJ's Zytiga in a late-stage pre-chemo prostate cancer study lived 27.2 months vs. 21.7 months for Provenge.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)